2†
The IL-23 inhibitor from AbbVie for patients 6 years of age and older with active psoriatic arthritis (PsA) or with moderate to severe plaque psoriasis (Ps) who are candidates for systemic therapy or phototherapy.1
SKYRIZI COMPLETE
Skyrizi Complete provides you with a dedicated point of contact and supports you throughout the prescription journey
When you enroll patients at the time of prescription, you activate:
Dedicated Field Reimbursement
Manager (FRM)
who provides Rheumatology expertise in insurance policies and case-by-case personalized support to help prevent delays and denials
360° Access
Support
including comprehensive access and reimbursement support, educational resources, Specialty Pharmacy coordination, and market access disruptors support
Patient
Affordability
with financial support options so patients can access, start, and stay on track with their prescribed SKYRIZI treatment plan
Support for
Your Patients
from a Skyrizi Complete Ambassador* and guidance from an Insurance Specialist to help meet their individual needs along their treatment journey
*Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing health care professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.
Three ways to enroll your patients in Skyrizi Complete today
Download the Skyrizi Complete
Enrollment and Prescription Form
and fax it to 1-678-727-0690
Call 1-877-COMPLETE
(1-877-266-7538) to enroll patients
by phone
2†
A dedicated point of contact who supports you in navigating the prescription journey for your patients
Your FRM provides expertise in insurance policies and case-by-case, personalized educational support to help prevent delays and denials for your patients.
Supporting you in navigating:
- Prior Authorization
- Financial Assistance
- Specialty Pharmacy Coordination
†As selected by 400 Allied Healthcare Professionals independently surveyed by Nuvera in 2025.2
Get connected with your FRM
Activate 360º access support
Skyrizi Complete provides comprehensive access and reimbursement support, educational resources, and fulfillment coordination support.
Support for your patients with Skyrizi Complete
Patient Affordability
Financial support options so patients can access, start, and stay on track with SKYRIZI treatment as prescribed
- Eligible, commercially insured patients may pay as little as $0 copay per treatment‡
- With Complete Rebate, patients may be reimbursed for certain out-of-pocket costs associated with their treatment‡
- Education on improved affordability for patients with Medicare Part D coverage including information about Medicare Prescription Payment Plan
Personalized Assistance
Every patient receives assistance and guidance to help meet their individual needs
- 1:1 support from an Ambassador to explain financial savings options, answer questions, provide supplemental injection training, and help with treatment coordination
- Insurance Specialist to explain insurance coverage, including Medicare Part D, open enrollment, and market access disruptors support. They can also discuss cost-saving options regardless of insurance status.
- Complete App to help them stay on track with their treatment plan, set reminders and more
‡Eligibility: Available to patients with commercial insurance coverage for SKYRIZI® (risankizumab-rzaa) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit SKYRIZISavingsCard.com or call 1.866.SKYRIZI for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy
More resources to help you get started
Find additional downloadable resources for navigating the prescription journey for your patients
4 DOSES PER YEAR
4 doses per year after 2 initiation doses at Weeks 0 and 41
ACR 20/50/70 RESPONSE RATES
In patients with PsA at Week 24 and up to ~6 years1,3
Primary endpoint ACR20 at Week 241
